---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-019083"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:32:42.951850+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst completes $160M acquisition of U.S. rights to FYCOMPA from Eisai, expects accretion in 2023

## Summary
- Paid $160M upfront all-cash to Eisai; potential milestone/royalty payments under certain conditions.
- FYCOMPA net revenue for FY ending March 31, 2023 expected ~$136M; gross margin similar to FIRDAPSE.
- Eisai will supply FYCOMPA for 7 years and provide transition services for up to 180 days post-closing.
- Acquisition expected to be accretive to EBITDA and EPS in 2023; FIRDAPSE revenue guidance unchanged at $205-210M.
- Overlaps ~45% with FIRDAPSE physician call points; strengthens neuroscience portfolio.

## SEC filing metadata
- accession: 0001193125-23-019083
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/0001193125-23-019083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/d103110d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-019083
- JSON: https://secwatch.observer/filing/0001193125-23-019083.json
- Plain text: https://secwatch.observer/filing/0001193125-23-019083.txt

## Key facts
- M&A Transactions
  CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Eisai Co., Ltd. for $160 million (closed 2023-01-24).
  - Action: acquisition
  - Counterparty: Eisai Co., Ltd.
  - Consideration: $160 million
  - Closing: 2023-01-24
  source text: Asset Purchase Agreement (the “ Purchase Agreement ”) between the Company and Eisai. Under the terms of the Purchase Agreement, the Company paid an upfront payment to Eisai of $160 million. Also at the closing of the asset purchase, the parties entered into two related agreements: (i) a short term Transition Services Agreement (the “ Transition Services Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312523019083/0001193125-23-019083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.